BIO Deutschland names important success factors for vaccine production

Press release

German biotechnology companies have not only developed coronavirus vaccines, they are also an integral part of the manufacturing process for these vaccines. As suppliers of precursors and raw materials, they strengthen the entire value chain for urgently needed vaccines with their expertise and production facilities. In a manufacturers’ statement, BIO Deutschland has now published important success factors for the rapid and reliable ramp-up of vaccine production. In order to improve processes and speed up the roll-out of vaccines, approvals for biotechnological processes, products and plants must be accelerated and supported by regulatory bodies in the best possible way. In addition, financial security for what has become the inevitable and comprehensive stockpiling of larger quantities of critical production components is urgently needed. This ensures that production will not come to a standstill and that the many risks undertaken by companies can be cushioned. The entrepreneurs also call for harmonising production approval procedures within the EU and supporting European suppliers. Entrepreneurs from the biotechnology sector formulated these and other improvement proposals in their statement.

The manufacturers’ statement (in English) can be found here.